Which has preferable valuation and earnings, GNLX or KYNB?

Kyntra Bio has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 11,219.52 -$32.15M -$0.86 N/A Kyntra Bio $6.44M 4.36 $183.45M $45.30 0.15

Is GNLX or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Genelux's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Kyntra Bio 2,199.13% N/A -47.27%

Does the media prefer GNLX or KYNB?

In the previous week, Genelux and Genelux both had 4 articles in the media. Genelux's average media sentiment score of 1.15 beat Kyntra Bio's score of 0.36 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer COYA or KYNB?

In the previous week, Kyntra Bio had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Kyntra Bio and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.61 beat Kyntra Bio's score of 0.36 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate KYNB or DTSQ?

Kyntra Bio presently has a consensus target price of $37.25, indicating a potential upside of 436.74%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, KYNB or DTSQ?

Kyntra Bio has higher revenue and earnings than DT Cloud Star Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.36 $183.45M $45.30 0.15 DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is KYNB or DTSQ more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to DT Cloud Star Acquisition's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% DT Cloud Star Acquisition N/A N/A N/A

Does the media refer more to KYNB or DTSQ?

In the previous week, Kyntra Bio had 1 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Kyntra Bio and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.04 beat Kyntra Bio's score of 0.36 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DT Cloud Star Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRDF or KYNB?

In the previous week, Kyntra Bio had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Kyntra Bio and 3 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.46 beat Kyntra Bio's score of 0.36 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kyntra Bio (KYNB) Competitors

$6.94 -0.06 (-0.86%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.05 +0.11 (+1.63%)

As of 09/25/2026 05:03 PM Eastern

Compare

KYNB vs. GNLX, COYA, BDTX, DTSQ, and CRDF

Should you buy Kyntra Bio stock or one of its competitors? Kyntra Bio's main competitors and comparable companies include Genelux (GNLX), Coya Therapeutics (COYA), Black Diamond Therapeutics (BDTX), DT Cloud Star Acquisition (DTSQ), and Cardiff Oncology (CRDF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyntra Bio compare to Genelux?

Genelux (NASDAQ:GNLX) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Kyntra Bio has a net margin of 2,199.13% compared to Genelux's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Kyntra Bio	2,199.13%	N/A	-47.27%

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 625.81%. Kyntra Bio has a consensus target price of $37.25, indicating a potential upside of 436.74%. Given Genelux's stronger consensus rating and higher probable upside, research analysts clearly believe Genelux is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

37.3% of Genelux shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kyntra Bio has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,219.52	-$32.15M	-$0.86	N/A
Kyntra Bio	$6.44M	4.36	$183.45M	$45.30	0.15

In the previous week, Genelux and Genelux both had 4 articles in the media. Genelux's average media sentiment score of 1.15 beat Kyntra Bio's score of 0.36 indicating that Genelux is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genelux has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Summary

Kyntra Bio beats Genelux on 10 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Coya Therapeutics' net margin of -270.22%. Kyntra Bio's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Kyntra Bio	2,199.13%	N/A	-47.27%

Kyntra Bio has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	14.99	-$21.23M	-$1.07	N/A
Kyntra Bio	$6.44M	4.36	$183.45M	$45.30	0.15

Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 201.84%. Kyntra Bio has a consensus price target of $37.25, indicating a potential upside of 436.74%. Given Kyntra Bio's higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Kyntra Bio had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Kyntra Bio and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.61 beat Kyntra Bio's score of 0.36 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kyntra Bio beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Black Diamond Therapeutics?

Kyntra Bio (NASDAQ:KYNB) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Kyntra Bio has a net margin of 2,199.13% compared to Black Diamond Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Kyntra Bio has higher earnings, but lower revenue than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.36	$183.45M	$45.30	0.15
Black Diamond Therapeutics	$70M	1.54	$22.37M	-$0.75	N/A

Kyntra Bio has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.31, indicating that its stock price is 231% more volatile than the broader market.

Kyntra Bio currently has a consensus price target of $37.25, indicating a potential upside of 436.74%. Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 445.21%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Kyntra Bio had 3 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Kyntra Bio and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.86 beat Kyntra Bio's score of 0.36 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kyntra Bio	Neutral
Black Diamond Therapeutics	Very Positive

Summary

Black Diamond Therapeutics beats Kyntra Bio on 9 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to DT Cloud Star Acquisition?

Kyntra Bio (NASDAQ:KYNB) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

72.7% of Kyntra Bio shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Kyntra Bio had 1 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Kyntra Bio and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.04 beat Kyntra Bio's score of 0.36 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DT Cloud Star Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has higher revenue and earnings than DT Cloud Star Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.36	$183.45M	$45.30	0.15
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Kyntra Bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Kyntra Bio presently has a consensus target price of $37.25, indicating a potential upside of 436.74%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kyntra Bio has a net margin of 2,199.13% compared to DT Cloud Star Acquisition's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
DT Cloud Star Acquisition	N/A	N/A	N/A

Summary

Kyntra Bio beats DT Cloud Star Acquisition on 8 of the 11 factors compared between the two stocks.

How does Kyntra Bio compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Kyntra Bio has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	163.49	-$45.85M	-$0.60	N/A
Kyntra Bio	$6.44M	4.36	$183.45M	$45.30	0.15

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Kyntra Bio had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Kyntra Bio and 3 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.46 beat Kyntra Bio's score of 0.36 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has a net margin of 2,199.13% compared to Cardiff Oncology's net margin of -7,885.43%. Kyntra Bio's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Kyntra Bio	2,199.13%	N/A	-47.27%

Cardiff Oncology currently has a consensus target price of $7.50, indicating a potential upside of 504.84%. Kyntra Bio has a consensus target price of $37.25, indicating a potential upside of 436.74%. Given Cardiff Oncology's higher probable upside, research analysts clearly believe Cardiff Oncology is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cardiff Oncology has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Kyntra Bio beats Cardiff Oncology on 11 of the 16 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.34M	$3.91B	$7.29B	$13.11B
Dividend Yield	N/A	3.63%	2.52%	13.50%
P/E Ratio	0.15	14.15	275.84	25.78
Price / Sales	4.36	1,338.96	614.77	84.39
Price / Cash	N/A	118.05	79.23	52.93
Price / Book	-1.65	15.28	10.44	6.30
Net Income	$183.45M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-1.84%	-2.94%	-1.31%	-0.23%
1 Month Performance	-14.32%	-8.85%	-4.72%	-3.87%
1 Year Performance	N/A	29.07%	14.96%	5.38%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	3.8857 of 5 stars	$6.94 -0.9%	$37.25 +436.7%	N/A	$28.34M	$6.44M	0.15	570	News Coverage
GNLX Genelux	2.7286 of 5 stars	$2.53 flat	$18.00 +611.5%	-41.1%	$114.47M	$10K	N/A	26	News Coverage Analyst Downgrade
COYA Coya Therapeutics	2.1839 of 5 stars	$4.89 +2.7%	$15.33 +213.6%	-4.3%	$111.66M	$7.95M	N/A	8	Analyst Forecast High Trading Volume
BDTX Black Diamond Therapeutics	3.3146 of 5 stars	$1.96 +1.6%	$10.25 +423.0%	-39.5%	$110.89M	$70M	N/A	21	High Trading Volume
DTSQ DT Cloud Star Acquisition	1.3565 of 5 stars	$11.58 +0.7%	N/A	+9.2%	$102.36M	N/A	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. GNLX, COYA, BDTX, DTSQ, and CRDF

How does Kyntra Bio compare to Genelux?

Summary

How does Kyntra Bio compare to Coya Therapeutics?

Summary

How does Kyntra Bio compare to Black Diamond Therapeutics?

Summary

How does Kyntra Bio compare to DT Cloud Star Acquisition?

Summary

How does Kyntra Bio compare to Cardiff Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. GNLX, COYA, BDTX, DTSQ, and CRDF

How does Kyntra Bio compare to Genelux?

Is GNLX or KYNB more profitable?

Do analysts rate GNLX or KYNB?

Do insiders and institutionals have more ownership in GNLX or KYNB?

Which has preferable valuation and earnings, GNLX or KYNB?

Does the media prefer GNLX or KYNB?

Which has more risk and volatility, GNLX or KYNB?

Summary

How does Kyntra Bio compare to Coya Therapeutics?

Which has more risk & volatility, COYA or KYNB?

Is COYA or KYNB more profitable?

Which has better valuation and earnings, COYA or KYNB?

Do analysts rate COYA or KYNB?

Do institutionals and insiders believe in COYA or KYNB?

Does the media prefer COYA or KYNB?

Summary

How does Kyntra Bio compare to Black Diamond Therapeutics?

Is KYNB or BDTX more profitable?

Which has better earnings and valuation, KYNB or BDTX?

Which has more volatility and risk, KYNB or BDTX?

Do analysts rate KYNB or BDTX?

Do institutionals & insiders have more ownership in KYNB or BDTX?

Does the media refer more to KYNB or BDTX?

Summary

How does Kyntra Bio compare to DT Cloud Star Acquisition?

Do institutionals and insiders have more ownership in KYNB or DTSQ?

Does the media refer more to KYNB or DTSQ?

Which has higher valuation and earnings, KYNB or DTSQ?

Which has more risk & volatility, KYNB or DTSQ?

Do analysts rate KYNB or DTSQ?

Is KYNB or DTSQ more profitable?

Summary

How does Kyntra Bio compare to Cardiff Oncology?

Which has better earnings & valuation, CRDF or KYNB?

Do insiders & institutionals have more ownership in CRDF or KYNB?

Does the media prefer CRDF or KYNB?

Is CRDF or KYNB more profitable?

Do analysts prefer CRDF or KYNB?

Which has more volatility & risk, CRDF or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools